This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
Key points:
* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days * Doctors will monitor liver health through blood tests and ultrasound scans * The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.
Main measurements:
* Changes in liver enzyme levels (ALT, AST) * Reduction in liver size * Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics
Age 18 to 65 years
Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)
Hepatomegaly confirmed by ultrasound (≥3 cm craniocaudal liver enlargement)
ALT level between 90-150 U/L
Liver cirrhosis or hepatocellular carcinoma
Pregnancy or lactation
Known allergy to any of the study medications or supplement components
Gallstones or biliary obstruction
Phenomen Pharma
Lead sponsor